Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Tipo de estudio
Intervalo de año de publicación
1.
Biomed Pharmacother ; 173: 116401, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38460363

RESUMEN

Adenosine regulates multiple physiological processes through the activation of four receptor subtypes, of which the A2B adenosine receptor (A2BAR) has the lowest affinity for adenosine. Being the adenosine receptor subtype most prominently expressed in epidermis, we recently described the antiproliferative and anti-inflammatory effect of the selective A2BAR agonist BAY60-6583 (BAY) in human keratinocytes stimulated with 12-O-tetradecanoylphorbol-13-acetate (TPA), so we sought to establish the effect of topical application of BAY in a model of murine epidermal hyperplasia. Topical application of BAY (1 or 10 µg/site) prevented the inflammatory reaction and skin lesions induced by TPA, minimizing hyperproliferation and acanthosis, as well as the expression of specific markers of proliferative keratinocytes. On the other hand, pre-treatment with the selective A2BAR antagonist, PSB-1115 (PSB, 5 or 50 µg/site) reversed these beneficial effects. Additionally, BAY application normalized the expression of epidermal barrier proteins, whose integrity is altered in inflammatory skin diseases, while treatment with the antagonist alone worsened it. Our results, besides confirming the anti-inflammatory and antiproliferative effects of the A2BAR agonist, further demonstrate a role of A2BAR activation to preserve the epidermal barrier. Therefore, the activation of A2BAR may constitute a possible new pharmacological target for the treatment of skin inflammatory diseases such as psoriasis.


Asunto(s)
Adenosina , Enfermedades de la Piel , Ratones , Animales , Humanos , Adenosina/farmacología , Adenosina/metabolismo , Receptor de Adenosina A2B/metabolismo , Hiperplasia/tratamiento farmacológico , Hiperplasia/patología , Modelos Animales de Enfermedad , Epidermis , Antiinflamatorios/farmacología , Enfermedades de la Piel/patología
2.
Microbes Infect ; 6(6): 542-8, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15158187

RESUMEN

Previous work by our group showed that Toll-like receptor 2 (TLR2) is essential for activation of innate immunity, playing a major role in the response of macrophages to Candida albicans, triggering cytokine and chemokine expression, and therefore TLR2 -/- mice are more susceptible to systemic primary candidiasis. In this work, we used a murine model of systemic C. albicans infection, in which resistance to reinfection with virulent wild-type cells is induced by prior exposure of mice to a low-virulence agerminative strain of C. albicans (primary sublethal infection), to study the influence of TLR2 gene deletion on (i) the ability to develop an acquired resistance upon vaccination; (ii) the development of the acquired humoral response; and (iii) the production of Th1 cytokines IFN-gamma, IL-12 and TNF-alpha. Our results indicate that, although TLR2 -/- mice have a very impaired production of Th1 cytokines compared with control mice, they are equally capable of mounting a specific humoral response to the fungus and developing a vaccine-induced resistance.


Asunto(s)
Anticuerpos Antifúngicos/sangre , Candida albicans/inmunología , Candidiasis/inmunología , Citocinas/biosíntesis , Glicoproteínas de Membrana/fisiología , Receptores de Superficie Celular/fisiología , Animales , Inmunidad Innata , Inmunoglobulina G/sangre , Interferón gamma/biosíntesis , Interleucina-12/biosíntesis , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptor Toll-Like 2 , Receptores Toll-Like , Factor de Necrosis Tumoral alfa/biosíntesis
3.
Eur J Pharmacol ; 488(1-3): 225-30, 2004 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-15044055

RESUMEN

In a previous study, we reported a new pyrazolo pyrimidine derivative, N(4)-benzyl-N(6),N(6)-dimethyl-1-1(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidine-6,4-diamine (DPP), which inhibited potently cyclooxygenase-2 activity in intact cell assays with minor activity against cyclooxygenase-1 (IC(50)=0.9 nM for cyclooxygenase-2 versus IC(50)=59.6 nM for cyclooxygenase-1). In the present work, this behaviour was confirmed in vivo by using the 24-h zymosan-injected mouse air pouch model (ID(50)=1.36 nM/pouch for prostaglandin E(2) level). We also studied the possible beneficial effect of DPP in the angiogenesis-dependent murine air pouch granuloma and rat paw carrageenan-induced hyperalgesia models. DPP exerted analgesic and anti-angiogenic (52% reduction in angiogenesis at 10 mg/kg, i.p.) effects that may be associated with inhibition of cyclooxygenase-2 activity.


Asunto(s)
Inhibidores de la Angiogénesis/farmacología , Inhibidores de la Ciclooxigenasa/farmacología , Isoenzimas/metabolismo , Prostaglandina-Endoperóxido Sintasas/metabolismo , Pirazoles/farmacología , Pirimidinas/farmacología , Animales , Carragenina , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Dinoprostona/metabolismo , Edema/inducido químicamente , Edema/prevención & control , Femenino , Granuloma/inducido químicamente , Granuloma/patología , Interleucina-1/biosíntesis , Ratones , Neovascularización Patológica/patología , Neovascularización Patológica/prevención & control , Nitrobencenos/farmacología , Ratas , Ratas Wistar , Sulfonamidas/farmacología , Factor de Necrosis Tumoral alfa/biosíntesis , Zimosan
4.
Eur J Med Chem ; 37(8): 699-705, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12161067

RESUMEN

A series of nine dimethylamino-chalcone derivatives (1,3-diaryl-propenones) was synthesized and screened as potential inhibitors of NO and PGE(2) production in the RAW 264.7 macrophage cell line. 4-Dimethylamino-2',5'-dimethoxychalcone (6) was found to be the most potent and dual inhibitor (IC(50s) in the submicromolar range) of NO and PGE(2) production. 2',6'-Dimethoxylation appeared to be an effective requirement for selective and potent inhibition of nitric oxide synthase induction as it was confirmed by Western blot analysis. Chalcone (6) at 25 mg kg(-1) by oral route, inhibited significantly the formation of oedema in the carrageenan-induced model of inflammation in mice.


Asunto(s)
Antiinflamatorios/síntesis química , Chalcona/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Administración Oral , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacología , Línea Celular , Chalcona/administración & dosificación , Chalcona/síntesis química , Dimetilaminas/administración & dosificación , Dimetilaminas/síntesis química , Dimetilaminas/farmacología , Dinoprostona/antagonistas & inhibidores , Dinoprostona/biosíntesis , Evaluación Preclínica de Medicamentos , Edema/tratamiento farmacológico , Edema/prevención & control , Inducción Enzimática/efectos de los fármacos , Macrófagos/citología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratones , Óxido Nítrico Sintasa/biosíntesis , Óxido Nítrico Sintasa de Tipo II , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA